C4 Therapeutics (CCCC) Interest Expenses (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Interest Expenses of $2.3 million for Q1 2026, up 3.02% year-over-year from $2.2 million in Q1 2025, and up 3827.12% quarter-over-quarter from $59000.0 in Q4 2025.
C4 Therapeutics (CCCC) Interest Expenses (2019 - 2026) Analysis & Trends
C4 Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 3.02% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $136000.0 (up 101.79% YoY), while the FY2025 annual figure was $203.6 million, up 17.34% from the prior year.
- Interest Expenses for Q1 2026 stood at $2.3 million, up from $59000.0 in the prior quarter.
- The five-year high for Interest Expenses was $103.9 million in Q1 2022, with the low at -$6.6 million in Q4 2024.
- The 5-year median for Interest Expenses is $911000.0 (2023), against an average of $17.8 million.
- Peak annual rise in Interest Expenses reached 2002.71% in 2022, while the deepest fall reached 1553.36% in 2022.
- C4 Therapeutics' Interest Expenses stood at -$3.5 million in 2022, then tumbled by 57.01% to -$5.4 million in 2023, then fell by 21.78% to -$6.6 million in 2024, then surged by 100.89% to $59000.0 in 2025, then soared by 3827.12% to $2.3 million in 2026.
- Business Quant data shows CCCC's Interest Expenses at $2.3 million in Q1 2026, $59000.0 in Q4 2025, and $9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 449,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 449,000.00 |
| Jun 30, 2026 | 449,000.00 |
| Mar 31, 2026 | 2.32 Mn |
| Mar 31, 2026 | 2.32 Mn |
| Dec 31, 2025 | 59,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 2.25 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | -6.61 Mn |
| Dec 31, 2024 | -6.61 Mn |
| Sep 30, 2024 | 45,000.00 |
| Sep 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 448,000.00 |
| Jun 30, 2024 | 448,000.00 |
| Mar 31, 2024 | 2.18 Mn |
| Mar 31, 2024 | 2.18 Mn |